Casirivimab and Imdevimab Treatment in Seropositive, Hospitalized COVID-19 Patients With Non-neutralizing or Borderline Neutralizing Antibodies
Andrea T. Hooper, Selin Somersan-Karakaya, Shane E. McCarthy, Eleftherios Mylonakis, Shazia Ali, Jingning Mei, Rafia Bhore, Adnan Mahmood, Gregory P. Geba, Paula Dakin, David M. Weinreich, George D. Yancopoulos, Gary A. Herman, Jennifer D. Hamilton, the COVID-19 Phase 2/3 Hospitalized Trial Team
doi: https://doi.org/10.1101/2022.06.14.22276389
Andrea T. Hooper
aRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
Selin Somersan-Karakaya
aRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
Shane E. McCarthy
aRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
Eleftherios Mylonakis
bBrown University, Providence, Rhode Island, USA
Shazia Ali
aRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
Jingning Mei
aRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
Rafia Bhore
aRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
Adnan Mahmood
aRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
Gregory P. Geba
aRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
Paula Dakin
aRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
David M. Weinreich
aRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
George D. Yancopoulos
aRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
Gary A. Herman
aRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
Jennifer D. Hamilton
aRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
Article usage
Posted June 14, 2022.
Casirivimab and Imdevimab Treatment in Seropositive, Hospitalized COVID-19 Patients With Non-neutralizing or Borderline Neutralizing Antibodies
Andrea T. Hooper, Selin Somersan-Karakaya, Shane E. McCarthy, Eleftherios Mylonakis, Shazia Ali, Jingning Mei, Rafia Bhore, Adnan Mahmood, Gregory P. Geba, Paula Dakin, David M. Weinreich, George D. Yancopoulos, Gary A. Herman, Jennifer D. Hamilton, the COVID-19 Phase 2/3 Hospitalized Trial Team
medRxiv 2022.06.14.22276389; doi: https://doi.org/10.1101/2022.06.14.22276389
Casirivimab and Imdevimab Treatment in Seropositive, Hospitalized COVID-19 Patients With Non-neutralizing or Borderline Neutralizing Antibodies
Andrea T. Hooper, Selin Somersan-Karakaya, Shane E. McCarthy, Eleftherios Mylonakis, Shazia Ali, Jingning Mei, Rafia Bhore, Adnan Mahmood, Gregory P. Geba, Paula Dakin, David M. Weinreich, George D. Yancopoulos, Gary A. Herman, Jennifer D. Hamilton, the COVID-19 Phase 2/3 Hospitalized Trial Team
medRxiv 2022.06.14.22276389; doi: https://doi.org/10.1101/2022.06.14.22276389
Subject Area
Subject Areas
- Addiction Medicine (316)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2296)
- Dermatology (202)
- Emergency Medicine (371)
- Epidemiology (11621)
- Forensic Medicine (10)
- Gastroenterology (683)
- Genetic and Genomic Medicine (3623)
- Geriatric Medicine (340)
- Health Economics (622)
- Health Informatics (2329)
- Health Policy (918)
- Hematology (336)
- HIV/AIDS (758)
- Medical Education (361)
- Medical Ethics (101)
- Nephrology (393)
- Neurology (3389)
- Nursing (193)
- Nutrition (512)
- Oncology (1776)
- Ophthalmology (526)
- Orthopedics (211)
- Otolaryngology (284)
- Pain Medicine (226)
- Palliative Medicine (66)
- Pathology (441)
- Pediatrics (1012)
- Primary Care Research (409)
- Public and Global Health (6020)
- Radiology and Imaging (1237)
- Respiratory Medicine (814)
- Rheumatology (370)
- Sports Medicine (319)
- Surgery (390)
- Toxicology (50)
- Transplantation (171)
- Urology (143)